Enliven Therapeutics (NASDAQ:ELVN) Stock Breaks Below Fifty Day Moving Average - Time to Sell?

Enliven Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Enliven shares fell below their 50-day moving average, trading at $44.89 versus the $45.69 average; the stock remains above its 200-day average of $43.98.
  • Analysts maintain a “Moderate Buy” consensus with an average price target of $75.44. The company also reported a quarterly loss of $0.36 per share, narrower than analysts’ expected $0.45 loss.
  • Company insiders sold 25,036 shares worth about $1.14 million over the past three months, including sales by the CFO and a director.
  • Five stocks we like better than Enliven Therapeutics.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s share price crossed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $45.69 and traded as low as $44.72. Enliven Therapeutics shares last traded at $44.89, with a volume of 747,595 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ELVN. JPMorgan Chase & Co. assumed coverage on Enliven Therapeutics in a research note on Thursday, October 1st. They issued an "overweight" rating and a $75.00 price target for the company. Wall Street Zen raised shares of Enliven Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 7th. Mizuho lifted their target price on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the company an "outperform" rating in a research note on Tuesday, August 18th. Guggenheim reiterated a "buy" rating and issued a $78.00 target price on shares of Enliven Therapeutics in a research note on Friday, November 6th. Finally, Barclays started coverage on shares of Enliven Therapeutics in a research report on Tuesday, August 18th. They issued an "overweight" rating and a $78.00 target price for the company. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $75.44.

Check Out Our Latest Stock Report on Enliven Therapeutics

Enliven Therapeutics Price Performance

The company has a fifty day simple moving average of $45.69 and a two-hundred day simple moving average of $43.98. The company has a market capitalization of $3.30 billion, a P/E ratio of -26.25 and a beta of 0.34.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. Equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 6,018 shares of the firm's stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total value of $231,572.64. Following the transaction, the chief financial officer directly owned 38,000 shares of the company's stock, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the business's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the sale, the director owned 13,000 shares of the company's stock, valued at approximately $606,710. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 25,036 shares of company stock worth $1,141,289 over the last three months. 3.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently modified their holdings of the company. Algert Global LLC raised its position in shares of Enliven Therapeutics by 11.6% in the third quarter. Algert Global LLC now owns 80,470 shares of the company's stock valued at $3,689,000 after purchasing an additional 8,380 shares during the period. Aquatic Capital Management LLC lifted its stake in shares of Enliven Therapeutics by 51.5% in the third quarter. Aquatic Capital Management LLC now owns 12,730 shares of the company's stock worth $584,000 after buying an additional 4,330 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Enliven Therapeutics by 3.5% in the third quarter. Goldman Sachs Group Inc. now owns 333,292 shares of the company's stock worth $15,278,000 after buying an additional 11,136 shares during the last quarter. Entropy Technologies LP bought a new stake in shares of Enliven Therapeutics during the 3rd quarter worth $256,000. Finally, Jump Financial LLC bought a new stake in shares of Enliven Therapeutics during the 3rd quarter worth $333,000. Institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company's pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Enliven Therapeutics Right Now?

Before you consider Enliven Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.

While Enliven Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines